Sexual Dimorphism and Age Effects in CKD and Type 2 Diabetes in the CONFIDENCE Trial
The UACR-lowering response of finerenone and empagliflozin scaled linearly with age (10% per decade) and sex (~20% more among women). The benefit of combination therapy was independent of age and sex.
Authors
- Amy K. Mottl (ORCID: https://orcid.org/0000-0002-4258-1726)
- L Li
- Julio Rosenstock (ORCID: https://orcid.org/0000-0001-8324-3275)
- Janet B. McGill (ORCID: https://orcid.org/0000-0002-6228-6521)
- Carolina Aldworth
- Na Li (ORCID: https://orcid.org/0000-0001-6361-8463)
- Meike Brinker
- Rajiv Agarwal
- Hiddo J L Heerspink
- Masaomi Nangaku
- Johannes F E Mann
- Jennifer B Green
- Charlie Scott
- Muthiah Vaduganathan
- Peter Rossing
Institutions
- University of North Carolina at Chapel Hill (US)
- University of Copenhagen (DK)
- Brigham and Women's Hospital (US)
- University Medical Center Groningen (NL)
- Steno Diabetes Centers (DK)
- Bayer (United States) (US)
- University of Groningen (NL)
- Duke University (US)
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Washington University in St. Louis (US)
- Clinical Research Institute (US)
- Richard L. Roudebush VA Medical Center (US)
- Velocity Clinical Research (United States) (US)
- Kidney Centre (PK)
- Indiana University – Purdue University Indianapolis (US)
- Bayer (Germany) (DE)
- The University of Tokyo (JP)
- IT University of Copenhagen (DK)
Publication Details
- Journal
- Nephrology Dialysis Transplantation
- Published
- 2026-03-27
- DOI
- https://doi.org/10.1093/ndt/gfag075
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00